QuVa Pharma is an FDA-registered national, industry-leading 503B outsourcing services company that provides hospitals with essential medications in ready-to-administer injectable formats. The company emphasizes cGMP compliance, sterile pharmaceutical manufacturing, and high quality and safety standards. QuVa operates roughly 300,000 sq. ft. of capacity across four facilities and maintains a 200-SKU product portfolio. It serves approximately 2,000 hospital customers. The company highlights customer-focused services, transparency, and a patient-safety orientation to help hospitals meet patient care and operational needs. The announced financing is intended to help QuVa add more hospitals to its platform and expand its product portfolio. QuVa Pharma operates a platform for sterile compounding pharmacy services, offering a broad product portfolio across Pain Management, Anti-infective, OR Syringes, Labor and Delivery and other therapeutic areas. Its products are released only after sterility and potency testing with validation supporting appropriate beyond-use dating (BUD). The company has facilities in Sugar Land and Temple, Texas, and in New Jersey. QuVa plans to use the new funding to expand operations in Texas and accelerate completion of its New Jersey facility. By the fourth quarter it expects to have 240,000 square feet of 503B registered manufacturing capacity and roughly 500 employees. The company is led by co-founder and CEO Stuart Hinchen and has raised approximately $200M in total to date. QuVa Pharma is a newly formed national platform for sterile compounding pharmacy services that provides compounded sterile preparations to hospitals across the U.S. The company acquired the assets of Healix’s 503B compounding pharmacy services unit and operates a manufacturing facility in Sugar Land, Texas. That facility is registered with the U.S. Food and Drug Administration as an Outsourcing Facility under Section 503B. QuVa plans to use new capital to support creation, expand current operations, and open additional locations. The company expects to retain all current employees at the acquired facility and to grow the facility’s capacity and staff over time. Leadership includes co‑founders Stuart Hinchen (CEO) and Peter Jenkins (Chief Development Officer).

Total raised

$315M

Funding rounds

5

Latest round

Debt Financing

Latest activity

May 2021